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Abstract
Rationale, Aims, and Objectives: While different imaging and treatment options are
available in acute coronary syndrome (ACS) care, there is a lack of data regarding their
use across Europe. We examined the diagnostic and treatment strategies in patients
with known or suspected ACS as reported by physicians and identified variations in
responses across European countries and geographical areas.
Method: A web-based clinician survey focusing on ACS imaging and revascularization
treatments was circulated through email distribution lists and websites of European
professional societies in the field of cardiology. We collected information on respon-
dents' clinical setting and specialty. Reported percentages of patients receiving imaging
or treatment modalities and percentages of clinicians reporting to use modalities in a
range of clinical scenarios were analyzed. Statistical comparisons were performed.
Results: In total, 69 responses were received (Sweden [n = 20], United Kingdom [n = 16],
Northern/Western Europe [n = 17], Southern Europe [n = 9], and Central Europe [n = 7]).
Considerable variations between geographical areas were seen in terms of reported diag-
nostic modalities and treatment strategies. For example, when presented with the scenario
of a theoretical 45-year-old smoking female with a suspected ACS, 56% of UK clinicians
reported to use coronary computed tomography angiography, compared to only 10% of
Swedish clinicians (P = .002). Large variations were observed regarding the reported use
of fractional flow reserve by physicians for non-culprit lesions during invasive manage-
ment of myocardial infarction patients (44% in Sweden, 31% in the United Kingdom, and
30% in Northern/Western Europe vs non-use in Central and Southern Europe).
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Conclusions: In this survey, respondents reported different diagnostic and treatment
strategies in ACS care. These variations seem to have geographic components. Larger
studies or real world data are needed to verify these observations and investigate
their causes. More research is needed to compare the quality and efficiency of ACS
care across countries and explore pathways for improvement.
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1 | INTRODUCTION
Acute coronary syndrome (ACS) refers to conditions where the blood
supplied to the heart muscle gets suddenly blocked leading to the
death of cells in the heart tissues. In patients with suspected ACS,
several imaging or functional testing modalities may be used to estab-
lish the diagnosis and to identify patients who should undergo myo-
cardial revascularization. As different imaging and treatment options
are currently available in the field, this variety might leave room for
clinical practice variation at the European level.
Evidence suggests differences in ACS care and outcomes within
Europe.1 However, variations in clinical practice and outcomes in ACS
care have mainly been analyzed at a national level, providing informa-
tion about the relative patterns and performance of different hospitals
within individual countries.2 Although this information is crucial to
assess the performance of hospitals and identify inequalities in care at
the national level, between-country comparisons have received little
attention and would provide a complementary opportunity for learn-
ing from foreign health care systems and improving national perfor-
mances.2 Furthermore, given the lack of reliable data, establishing the
status of the use of cardiovascular imaging in Europe has been a prior-
ity for influential European associations in the field.3
While both surveys and registries are needed to verify whether
clinical practice is in line with guidelines,4 surveys offer the advantage
to present specific clinical cases and obtain detailed information about
diagnostic and management strategies.
In this context, we developed and used a web-based clinician sur-
vey to examine the diagnostic and treatment strategies reported by
respondents and to identify potential variations in responses between
countries or geographical areas within Europe. The focus was made
on diagnostic tests (including coronary imaging and functional assess-
ment) and revascularization treatment, in a range of clinical scenarios
encompassing patients with known or suspected ACS.
2 | METHODS
2.1 | Study design
In order to assess clinical practice in ACS in Europe, we conducted an
online clinician survey. The survey questions were formulated based
on expert opinion and feedback collected from a European expert
panel, which included five cardiologists and three radiologists.
A pilot phase was conducted before the survey was launched in
March 2017. The survey was conducted using the online software
“Google form” and was made available online. The target population
for dissemination included non-invasive and interventional cardiolo-
gists, radiologists, and emergency physicians (including those complet-
ing their specialization).
No financial incentive was offered to participants and survey
completion was voluntary. An ethics committee (EMC Rotterdam)
reviewed the protocol and survey questions and concluded that this
work was not subject to the Dutch law of medical research (WMO).
2.2 | Structure
A closed and structured format in English was chosen to enable clini-
cians to select their responses among multiple predefined choices.
First, an introduction provided the framework of the study and was
followed by general questions regarding the respondents' work set-
ting. Subsequently, respondents were asked about the diagnostic
workup and the proportions of high-risk and low- to intermediate-risk
patients suspected with ACS who would receive different imaging
modalities in the respondent's practice setting. Section 5 contained
questions about the treatments used for ST-elevation myocardial
infarction (STEMI) and non-ST segment elevation myocardial infarc-
tion (NSTEMI) patients while Section 6 focused on follow-up imaging.
Questions related to specific patient cases and clinical scenarios were
disseminated throughout the survey and are summarized in Table 1.
The survey questions can be found in Supporting Information. A pilot-
test phase was conducted after which the number of questions was
reduced.
2.3 | Dissemination
The online survey link was circulated through email distribution lists
and websites of national and European professional societies. The
Swedish Society of Cardiology, the British Society of Cardiovascular
Imaging, and the Radcliffe Cardiology group invited their members to
participate in the survey through personal emails. The survey was
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circulated via the website of the Bulgarian Society of Cardiology, the
Czech Nuclear Medicine Society, the European Society of Cardiovas-
cular Radiology, and the Hungarian Society of Cardiology, which com-
plemented this action with an announcement in their newsletter.
2.4 | Statistical analysis
Reported percentages of patients receiving imaging or treatment
modalities and percentages of respondents reporting to use different
invasive or non-invasive diagnostic tests or treatments were extracted
from the clinicians' responses. Non-invasive diagnostic tests comprise
anatomical imaging such as coronary computed tomography angiogra-
phy (CTA) or functional (or stress) tests, including exercise electrocar-
diogram (ECG), stress echocardiography, and scintigraphic or magnetic
resonance (MR) perfusion imaging. In ACS care, functional imaging is
used to assess the haemodynamic characteristics of the heart. Inva-
sive assessments require insertion of cardiac catheters and include
invasive coronary angiography and fractional flow reserve (FFR)
assessment during an interventional procedure.
Mean percentages were calculated for two countries (Sweden and
the United Kingdom) and three clusters of countries (Central Europe,
Northern/Western Europe, and Southern Europe) that were created
based on the geographic location of the respondents and expected com-
monalities in their health care system. Given the breakdown of partici-
pants per country, Sweden and the United Kingdom were extracted
from the Northern/Western Europe cluster and isolated for more
detailed analyses. Our statistical analyses rely on the assumption that
respondents can be considered to be independent observations. Based
on background information of the hospital (city, academic centre, and
number of MI diagnosed), the maximum possible number of respon-
dents coming from the same centre is very low, which means that the
potential influence of this possibility on the results is low.
The 95% confidence intervals (CIs) surrounding the mean esti-
mates were computed using bootstrapping.5 This involved randomly
resampling the original samples with replacement 500 times, which
corresponded to the number of replications needed to ensure stability
and accuracy. Each bootstrapped sample yielded a bootstrap statistic
(eg, mean frequency). The bootstrap distribution was computed from
the 500 bootstrap statistics, per geographic area. Between-country
and between-cluster comparisons of imaging and treatments were
conducted using one-way ANOVA tests in SPSS (version 23). Statisti-
cal significance of the results was tested using a .05 level.
2.5 | General background regarding the availability
and use of imaging modalities in the European Union
Previous studies reported considerable variation in the availability and
use of imaging equipment in the European Union (EU). In 2015, Luxem-
bourg recorded the highest number of angiography units per capita,
followed by Italy and Sweden (Table 2).6 Germany and Italy reported
more than 2.8 magnetic resonance imaging (MRI) units per 100 000
inhabitants, in contrast to 0.4 MRI units per 100 000 inhabitants in
Hungary. In 2016, Luxembourg and France had the highest number of
CT scans per capita in the EU (21 100 scans and 20 400 scans per
100 000 inhabitants). Furthermore, while Sweden, and Northern
Europe in general, are known for their early adoption of medical tech-
nologies, Eastern European countries tend to be late adopters.7,8
3 | RESULTS
We received responses from 74 clinicians. Of those, four non-European
clinicians and one non-interpretable response set were excluded from
the analysis. Among the 69 remaining respondents, 20 were from Swe-
den, 16 from the United Kingdom, 7 from Central Europe, 17 from
Northern/Western Europe, and 9 from Southern Europe. Given that the
survey was distributed by national professional societies, it was not pos-
sible to calculate the response rate. We acknowledge the fact that the
response rate might be small. Details about the respondents' character-
istics and work environment can be found in Table 3.
3.1 | Initial diagnostic workup
On the basis of all answers, ECG combined with biochemical tests was
reported as the mainstay of the first-line diagnostic workup for both
TABLE 1 Clinical scenarios as defined in the survey
Patient case
number Patient case Procedure surveyed
1 45-year-old female woman suspected with ACS, admitted in the emergency department.
She had no cardiovascular risk factor except for smoking during 20 y. She presents with
an atypical chest pain, her ECG is normal and her troponin result is low.
Further examination
2 65-year-old NSTEMI patient who received PCI of the culprit lesion and presents a relatively
good clinical status
Strategy for dealing with
suspected non-culprit
lesions
3 Patient over 50 years old, admitted to the health centre with chest pain and an ACS has
been ruled out
Usual diagnostic strategy after
an ACS was ruled out
Abbreviations: ACS, acute coronary syndrome; ECG, electrocardiogram; NSTEMI, non-ST segment elevation myocardial infarction; PCI, percutaneous
coronary intervention.
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high-risk patients (79%; 95% CI: 70%, 87%) and low- to intermediate-
risk patients (68%; 95% CI: 58%, 78%) admitted to a health centre in
Europe with chest pain and suspected ACS. Across the different investi-
gated areas, non-invasive test appears to respondents to play a greater
role to establish or rule out the diagnosis of an ACS in low- to
intermediate-risk patients than in high-risk patients. Indeed, while an
average of 64% of the low- to intermediate-risk patients were reported
to receive non-invasive imaging (with ECG plus biochemical tests, with
ECG only and with biochemical tests only), only 48% of the high-risk
patients were reported to receive it (see Figure S1).
3.2 | Diagnosis of a low risk patient
The first patient case described a 45-year-old woman suspected with
ACS admitted in the emergency department with no cardiovascular risk
factors except for smoking for 20 years, atypical chest pain, a normal
ECG, and a low troponin result. The respondents were asked to indicate
what further investigations they would perform. In this hypothetical
clinical case, the vast majority of the clinicians responded they would
opt for a combination of coronary CTA and/or echocardiogram and/or
stress tests (see Figure 1). The combination of tests reported by the
respondents can be found in Figure S2. On the basis of the responses,
stress tests (including treadmill, scintigram, stress echocardiogram, or
stress MRI) would be obtained by 43% to 65% of the respondents in
each of the five investigated areas. The use of coronary CTA was
reported to be the highest among UK respondents (56%) and lowest
among Swedish respondents (10%) (P = .002). Swedish and Southern
Europe respondents strongly favoured stress tests in this context.
Significantly more UK respondents (56%) than Swedish respon-
dents (10%) reported they would use coronary CTA (P = .002). Large
variations were also observed regarding the use of echocardiogram:
while 71% of the respondents from Central Europe reported they
would perform an echocardiogram, this was only 22% in Southern
Europe and 25% in the United Kingdom. Interestingly, throughout the
different geographic areas, a varying proportion of respondents (0%-
22%) reported they would not perform any further examination.
3.3 | Imaging modality guiding treatment decision
for patients with a high probability of ACS after
biochemical tests
Overall, European respondents reported that an average of 60% of
their patients presenting with a high probability of ACS after biochem-
ical tests receive echocardiogram (see Figure S3). Furthermore,
European respondents reported that an estimated 54% of their
patients receive invasive coronary angiography without FFR com-
pared to 37% receiving invasive coronary angiography with FFR.
TABLE 3 Respondents' characteristics
Number %
Number of respondents 69 100
Countries and clusters
Sweden
United Kingdom
Central Europe (Czech Republic,
Hungary, Romania, Serbia)
Northern and Western Europe
(Finland, France, Germany, Ireland,
Luxembourg, Netherlands)
Southern Europe (Greece, Italy, Spain,
Macedonia)
20
16
7
17
9
29%
23%
10%
25%
13%
Specialty
Cardiologist
Cardiologist and emergency physician
Cardiologist and PCI operator
Cardiologist, PCI operator and
emergency physician
Emergency physician
PCI operator
Radiologist
42
1
17
1
1
2
5
61%
1%
25%
1%
1%
3%
7%
Financing system
Public
Private
64
5
93%
7%
Teaching category
Academic hospital
Non-academic hospital
48
21
70%
30%
Abbreviation: PCI, percutaneous coronary intervention.
TABLE 2 Availability and use of imaging equipment in a set of selected EU countries (6)
Per 100 000 inhabitants
Availability Use
Angiography units (2015) CT scanners (2016) MRI units (2016) CT scanners (2016) MRI units (2016)
France 0.7 1.7 1.4 20 439 11 385
Germany 1.1 3.5 3.5 14 310a 13 616a
Hungary 0.6 0.9 0.4 11 619 4224
Italy 1.4 1.3a 2.8a 8129 6710
Luxembourg 1.6 1.7 1.2 21 064 8340
Spain 0.6 1.8 1.6 10 870 8245
Sweden 1.3 2.2 1.6 NA NA
United Kingdom NA 1 0.7 8470 5676
Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging.
a2015.
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Southern European respondents reported the lowest frequencies
of FFR combined with invasive coronary angiography. While UK
respondents reported using coronary CTA for an average of 14% of
their patients, Swedish respondents reported using it for only
3% (P = .04).
3.4 | Diagnosis after ruling out ACS
Figure 2 shows the frequencies of diagnostic tests for patients
over 50 years of age admitted with chest pain and after an ACS
was ruled out, based on the proportion of patients per test
reported by each respondent (patient case 3). For these typical
patients, UK respondents reported using bicycle ECG less often
than the other European respondents. The difference between
British and Swedish respondents was statistically significant (4.5%
vs 57%; P = .00). Interestingly, UK respondents appear to be
almost equally divided between performing stress echocardiogram,
coronary CT scan, and invasive coronary angiography, with fre-
quency rates close to 20% for each test. UK respondents,
together with Northern/Western Europe respondents, reported
the highest frequencies of stress MRI: 15% and 15.5%, respec-
tively. On average, English respondents estimated that 15% of
their patients matching the hypothetical case 3 description
receive stress MRI, which means that this imaging modality is
significantly more often reported in the United Kingdom than in
Sweden, Central Europe, and Southern Europe (P < .05), in the
described context. The reported use of stress MRI also appears
F IGURE 1 Percentages of clinicians reporting to use different examinations in the diagnosis of a low risk patient (patient case 1)
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to be significantly greater in London than in other UK cit-
ies (P < .01).
3.5 | Average time between diagnosing a NSTEMI
patient and performing invasive coronary angiography
The reported time between diagnosing an NSTEMI patient and per-
forming invasive coronary angiography appear to vary substantially
between and within the investigated areas. While 18% of the whole
group of respondents (12/69) estimated an average time of 24 hours
between diagnosis and invasive coronary angiography, 52% (36/69)
of these respondents reported a delay of more than 24 hours. Of
these 36 respondents, 13 estimated a delay of at least 72 hours,
hence a total of 19% (13/69) of the whole group. Interestingly, while
45% (9/20) of the Swedish respondents reported performing coronary
angiography within 24 hours, all UK respondents estimated this delay
to be greater than 24 hours.
3.6 | Reperfusion treatment method for patients
presenting with a STEMI and revascularization
treatment method for patients presenting with a
primary NSTEMI
Figure 3 shows the reported frequencies of reperfusion treatments
and revascularization treatments given to STEMI patients (A) and
NSTEMI patients (B), respectively, who were not contra-indicated
for any treatment. Percutaneous coronary intervention (PCI) was
reported as the primary treatment modality for both STEMI and
NSTEMI patients. This was the case in all geographical areas,
although the actual percentage varied somewhat between geo-
graphical areas, with ranges of 77% to 96% for STEMI patients and
67% to 91% for NSTEMI patients. For the two categories of
patients, the lowest rates of PCI were reported in the Unit-
ed Kingdom. The UK respondents also reported the highest rate of
intravenous thrombolysis, with nearly 14% of their STEMI patients
receiving it, compared to an average of 2% to 6% reported in the
other geographic areas. Regarding the NSTEMI group, UK respon-
dents reported the highest rate of coronary artery bypass grafting
(CABG) (19%) across the investigated areas.
3.7 | Treatment of non-culprit lesions
In a second patient case, respondents were asked about how they
would treat suspected non-culprit lesions in a 65-year-old NSTEMI
patient presenting with a relatively good clinical status following the PCI
of the culprit lesion. For this typical patient, slightly more than one-
quarter of the whole group of European respondents (19/69 = 28%)
reported they would opt for conservative management with PCI only in
the case of symptoms or reversible ischemia on stress tests (see
Figure 4). Despite this trend, large variations are observed between
responses across geographical areas: while this strategy was chosen by
56% and 57% of the respondents in Southern Europe and Central
Europe, respectively, it was selected by only 16% to 25% of the respon-
dents in the United Kingdom, Sweden, and Northern/Western Europe.
The strategy of FFR was chosen by 26% (18/69) of the total group:
16% (11/69) of the whole European respondents opted for an immedi-
ate FFR-guided PCI during index catheterization, 9% (6/69) for a staged
FFR-guided PCI during index hospitalization, and one respondent opted
for a staged FFR-guided PCI between 4 and 8 weeks. Among the
respondents reporting PCI, the strategy of immediate PCI was most
prevalent in the United Kingdom and Sweden (67% and 36%, respec-
tively) (Figure 4B). No clinician from Southern Europe reported FFR-
guided PCI or immediate PCI in case of non-culprit lesions (Figure 4B).
F IGURE 2 Reported percentages of patients receiving different diagnostic strategies after an ACS was ruled out (patient case 3). ACS, acute
coronary syndrome
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Totals per country do not sum up to 100% due to respondents
who reported a “I do not know” answer.
4 | DISCUSSION
To the best of our knowledge, this study presents the first online sur-
vey aimed at describing and analyzing reported diagnostic and treat-
ment practices in ACS care across European regions and countries.
This study also provides detailed data related to a range of clinical sce-
narios that focus on strategies for specific patients.
Considerable variations in the respondents' answers were observed
in both the diagnostic and treatment phases of patients with known or
suspected ACS. In addition, comparative analyses revealed significant
differences between the responses from Swedish and UK clinicians.
4.1 | Availability and reimbursement of diagnostic
tests
The survey results showed that significantly lower frequencies of CTA
use were reported by the Swedish respondents compared to the UK
F IGURE 3 A, Reported percentages of
STEMI patients receiving different
reperfusion treatments. B, Reported
percentages of NSTEMI patients receiving
different revascularization treatments.
NSTEMI, non-ST segment elevation
myocardial infarction; STEMI, ST-elevation
myocardial infarction
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respondents. This may be explained by the facts that CTA is increas-
ingly but not widely available in Sweden9 and that CTA was incorpo-
rated into the UK NICE guidelines for patients at low risk of CAD.10
By means of the specific patient cases presented in the survey, MRI
was significantly more often reported by UK respondents than by
Swedish respondents. Furthermore, respondents from London
reported MRI to be more frequently used than respondents from
other UK cities. These studies showed a rapid increase in use of car-
diac MRI in patients with ACS and striking variations in use between
high volume centres, in and around London, and the rest of the coun-
try.11 A major factor that might explain the wide availability and the
increased use of MRI scanners in the United Kingdom is the fact that
F IGURE 4 A, Percentages of clinicians reporting their most common strategy in treating non-culprit lesions (patient case 2). B, Percentages of
clinicians reporting different approaches when performing PCI of the non-culprit lesion (patient case 2). PCI, percutaneous coronary intervention
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cardiac MRI is funded for assessment of ischaemic heart disease
(including suspected ACS) and other heart diseases. The situation is
different in many other European countries where different reim-
bursement schemes are in place and issues regarding reimbursement
may need to be solved.12 Further research would be needed to assess
whether the geographical imbalance observed in the responses within
and between countries reflects an overuse in the United Kingdom,
and especially in London, or underuse patterns outside of London and
in other European countries. As cardiac MRI is an accepted modality
for assessment of suspected coronary disease, the question of poten-
tial overuse mainly relates to the cost-effectiveness of the test.
Although the value of FFR to evaluate intermediate lesions or
guide selection of lesions for revascularization in patients with multi-
vessel disease is widely accepted,13 modest rates were reported in this
survey. This observation might reflect a low use or even a low imple-
mentation of FFR in Europe. It might also relate to the fact that the
prognostic role of FFR in guiding myocardial revascularization in
patients with an ACS needs additional clarification.14,15 Although FFR-
guided PCI has been proven to reduce mortality and MI compared to
angiography-guided PCI in patients with stable angina,16 considerable
differences were observed in the survey responses between regions
and countries. In that case again, reimbursement remains a major con-
straint preventing FFR from being widely utilized in Europe: differences
remain between countries that have allowed their hospitals to cover
the costs of FFR procedures (like the United Kingdom and Germany)
and other European countries where this is not reimbursed.17
4.2 | Guidelines
Our findings showed that the reported time between diagnosing an
NSTEMI patient and performing invasive coronary angiography varied
substantially between and within the geographical areas of the
respondents.
Although the European Society of Cardiology (ESC) guidelines
recommend revascularization within 24 hours in high-risk patients
and within 2 hours in very high-risk patients,15 this can be a challenge
in contemporary cardiac care in Europe. Achieving revascularization
within 24 hours was reported as a major challenge for Sweden in the
SWEDEHEART Annual report of 2017.9 National Institute for Health
and Care Excellence (NICE) guidelines recommend coronary angiogra-
phy within 72 hours for intermediate or higher risk patients.18 We
think that the influence of NICE guidelines in the United Kingdom
might partly explain why the times reported by UK respondents show
a shift towards later intervention compared to the times reported by
the Swedish respondents.
4.3 | Treatments
The relatively high reported rates of PCI for reperfusion in STEMI
patients and for revascularization in NSTEMI patients might reflect a
widespread access to PCI throughout Europe. Despite this trend, lower
rates of PCI were reported by UK respondents and variations in the
answers were seen between all geographical areas; these two observa-
tions are consistent with previous studies.19 European respondents
reported PCI as the most common invasive treatment for STEMI and
NSTEMI patients, although the efficacy and durability of CABG over
PCI (for different groups of patients) was largely demonstrated.20,21
CABG remains highly recommended in patients characterized by multi-
vessel disease, diabetes, or lesion complexity. In Sweden, the volume of
CABG procedures has been declining over the past 35 years but con-
siderable differences in the proportion of CABG and PCI out of the
total of revascularization exist across hospitals.9 This large variability
might indicate that some patients do not receive the optimal treatment
and highlight that further studies would be needed to investigate the
optimal rates of CABG and PCI. Comprehensive research is needed on
barriers to implementation, and more generally, on factors and structure
that determine the diffusion, implementation, and variations in use of
PCI within and between European countries.
Finally, we analyzed clinicians' responses regarding whether and
when non-culprit lesions are treated and intended to identify possible
geographic trends. While guidelines recommend a staged approach in
the treatment of patients with STEMI and multi-vessel disease,13
there is no evidence supporting the superiority of a staged over an
immediate approach and no evidence regarding the best approach for
NSTEMI patients.22
By means of a survey, this study investigated clinical situations
where evidence might remain uncertain or lacking. Indeed, the survey
guaranteed that respondents answer to the exact same case, which
allows preliminary international comparisons in clinical areas where
registry data might not exist, capture limited details, be poor in quality,
or not be available to third parties.
5 | LIMITATIONS
As a main limitation of our study, we acknowledge that a limited num-
ber of responses was received, implying a risk of selection bias and
constraining generalizability of our results. Further research would be
needed to ascertain and generalize our findings. However, our results
are consistent with previous studies in the field and identify consider-
able differences in the reported strategies between areas.
6 | CONCLUSIONS
Our study revealed considerable variation in the reported modalities
of diagnostic and treatment strategies in patients with suspected or
established ACS across Europe. We have discussed potential causes
for the reported differences in the utilization of these techniques that
range from evidence regarding availability of techniques, guidelines,
and reimbursement. Such differences may indicate that some patients
do not receive the best available care and may have an important
impact on the quality of health care and patient outcomes across geo-
graphical areas.
PEULTIER ET AL. 9
Complementary research might be possible to gather generaliz-
able data and confirm these variations, investigate their causes and
assess how much they reflect health care inefficiency and result in
inequalities in patient outcomes. This could be done by either exploi-
ting existing high quality registries or setting them up with a specific
scope in terms of patient population. The latter might require consid-
erable resources though.
Further research investigating the country-specific cost-
effectiveness of diagnostic and treatment strategies in ACS care might
be needed to define the most cost-effective way for diagnosing and
treating patients per country. Such studies would inform national pol-
icy makers and help them decide what cardiovascular technologies to
promote and reimburse in order to maximize health gains and/or mini-
mize costs, in the context of their local specificities and constraints.
While large European studies such as the SPCCT (Spectral Photon
Counting CT) project aim at developing new technologies,23 stronger
evidence regarding current local care, by means of surveys or alterna-
tive methods, might be needed before the role and value of new imag-
ing modalities in the clinical arena can be assessed.
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